4-(1-cyclohexyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine | 933824-48-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(1-cyclohexyl-2-methyl-1H-imidazol-5-yl)-5-fluoro-N-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl}pyrimidin-2-amine
• 英文别名: [4-[[4-(3-Cyclohexyl-2-methylimidazol-4-yl)-5-fluoropyrimidin-2-yl]amino]phenyl]-(4-methylpiperazin-1-yl)methanone
• CAS: 933824-48-7
• 化学式: C₂₆H₃₂FN₇O
• 分子量: 477.585
• InChiKey: CODOVTCJFDTFPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  79.2
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease
  申请人：Andersson Lars

  公开号：US20090105252A1

  公开（公告）日：2009-04-23

  Compounds of formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the specification as a base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, processes for their preparation, new intermediates used therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  该专利涉及式I的化合物，其中R1，R2，R3，R4，R5，R6，R7，R8和R9如规范中所定义，作为基础物质或药物可接受的盐，溶剂或其盐的溶剂，以及制备它们的方法，其中使用了新的中间体，含有所述化合物的制药配方以及在治疗中使用所述化合物的用途。
• [EN] NEW THERAPEUTIC COMBINATION OF A GSK3 INHIBITOR AND AN A7-NICOTINIC AGONIST 960<br/>[FR] NOUVELLE COMBINAISON THÉRAPEUTIQUE D'INHIBITEUR DE GSK3 ET D'AGONISTE ALPHA-7 NICOTINIQUE 960
  申请人：ASTRAZENECA AB

  公开号：WO2009017454A1

  公开（公告）日：2009-02-05

  The present invention related to a combination of (a) a GSK3 inhibitor and (b) an α7- nicotinic agonist. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.
• [EN] NEW THERAPEUTIC COMBINATION OF AN ANTIPSYCHOTIC AND A GSK3 INHIBITOR 958<br/>[FR] NOUVELLE COMBINAISON THÉRAPEUTIQUE D'ANTIPSYCHOTIQUE ET D'INHIBITEUR DE GSK3 958
  申请人：ASTRAZENECA AB

  公开号：WO2009017453A1

  公开（公告）日：2009-02-05

  The present invention related to a combination of (a) an antipsychotic and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of psychiatric disorders; particularly, cognitive impairment disorders in psychotic disorders.
• [EN] A NEW COMBINATION OF (A) AN ALPHA-4-BETA-2 -NEURONAL NICOTINIC AGONIST AND (B) A GSK3 INHIBITOR<br/>[FR] NOUVELLE COMBINAISON (A) D'AGONISTE ALPHA-4-BÊTA-2-NEURONAL NICOTINIQUE ET (B) D'INHIBITEUR DE GSK3
  申请人：ASTRAZENECA AB

  公开号：WO2009017455A1

  公开（公告）日：2009-02-05

  The present invention related to a combination of (a) a α4β2-neuronal nicotinic agonist and (b) a GSK3 inhibitor. The invention further relates to pharmaceutical compositions comprising said combination and to methods of treating CNS disorders in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kits in treatment of CNS disorders such as dementia and/or Alzheimer's Disease.